







































Prenatal and Early Postnatal Diagnosis of Congenital
Toxoplasmosis in a Setting With No Systematic
Screening in Pregnancy
Tijana Stajner, MD, Branko Bobic, MD, PhD, Ivana Klun, DVM, PhD,
Aleksandra Nikolic, MD, PhD, Jelena Srbljanovic, MsPharm, Aleksandra Uzelac, BSc,
Irena Rajnpreht, BSc, and Olgica Djurkovic-Djakovic, MD, PhD
To determine the risk of congenital toxoplasmosis (CT) and provide
early (pre- or postnatal) identification of cases of CT in the absence of
systematic screening in pregnancy.
In the presented cross-sectional study, serological criteria were used
to date Toxoplasma gondii infection versus conception in 80 pregnant
women with fetal abnormalities or referred to as suspected of acute
infection, and in 16 women after delivery of symptomatic neonates. A
combination of serological, molecular (qPCR), and biological (bioas-
say) methods was used for prenatal and/or postnatal diagnosis of CT.
Most (77.5%) pregnant women were examined in advanced preg-
nancy. Of all the examined seropositive women (n¼ 90), infection
could not be ruled out to have occurred during pregnancy in 93.3%, of
which the majority (69%) was dated to the periconceptual period. CT
was diagnosed in 25 cases, of which 17 prenatally and 8 postnatally.
Molecular diagnosis proved superior, but the diagnosis of CT based on
bioassay in 7 instances and by Western blot in 2 neonates shows that
other methods remain indispensable.
In the absence of systematic screening in pregnancy, maternal
infection is often diagnosed late, or even only when fetal/neonatal
infection is suspected. In such situations, use of a complex algorithm
involving a combination of serological, biological, and molecular
methods allows for prenatal and/or early postnatal diagnosis of CT,
but lacks the preventive capacity provided by early maternal treatment.
(Medicine 95(9):e2979)
Abbreviations: AF = amniotic fluid, BA = bioassay, CT =
congenital toxoplasmosis, FB = fetal blood, HSDA = high
sensitivity direct agglutination assay, ISAgA = immunosorbent
agglutination assay, NB = neonatal blood, NPV = negative
predictive value, NRLT = National Reference Laboratory for
Toxoplasmosis, PPV = positive predictive value, qPCR =
quantitative (real-time) PCR, T.gondii = Toxoplasma gondii, WB =
Western blot.
INTRODUCTION
Toxoplasma gondii is a ubiquitous protozoan parasite esti-mated to infect one-third of the global population.1,2
Although generally mild and self-limiting in immunocompetent
individuals, T. gondii infection may cause life-threatening dis-
ease in the fetus and in the immunosuppressed host. Congenital
transmission remains a considerable burden on global health.3
Fetal infection may result in intrauterine death or clinical
symptomatology at birth, or be subclinical at birth, but unless
treated, visual or neurological sequelae may develop later in
life.4 This emphasizes the need for timely diagnosis
and treatment.
Vertical transmission of T. gondii may occur following
maternal primary infection, characterized by the presence of
actively dividing parasites in the bloodstream of the pregnant
woman. The risk of parasites reaching the fetus depends mostly
on the gestational age at the time of infection, increasing from
less than 10% in the first trimester, to 30% in the second and
70% to 90% in the third trimester,5 but infection acquired up to
2 months before conception may also endanger the fetus.6–13
This implies that for the assessment of fetal risk, dating of the
infection versus conception is of the utmost importance. As
infection is clinically manifested in not more than 10% of
cases,14 the diagnosis of infection in pregnancy relies on
serology. As a general rule, detection of specific IgM and
low avidity IgG antibodies indicates recent infection. However,
serological findings, particularly if initially performed in late
pregnancy, may be challenging to interpret. Even in the absence
of specific IgG antibodies, detection of specific IgM requires
further follow-up testing to exclude the possibility of early
infection.15 It is well known that specific IgM may last for
prolonged periods of time,16,17 and so can low avidity.18–20 On
the other hand, detection of high avidity IgG antibodies rules out
primary infection within the last 4 months. This means that not
even high avidity, if detected in late pregnancy, can rule out
infection in early pregnancy or close to conception,11–13,21 that
is in the periconceptual period (2 months prior to or following
the assumed date of conception).
Monthly serological screening of pregnant women allows
for the time of seroconversion to be established within a margin
of few weeks. However, systematic screening programs exist in
only a limited number of European countries (France, Austria,
Belgium, Norway, and part of Italy). In contrast, in an over-
whelming majority of the world countries, maternal T. gondii
infection in pregnancy may only be suspected based on fetal
symptomatology, and is often diagnosed in advanced
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pregnancy. To date maternal infection, late testing requires
additional refinement of the diagnostic criteria based on the
expected kinetics of specific IgM and maturation of specific IgG
avidity over time.
In Serbia, laboratory diagnosis is carried out in routine
laboratories, and patients with discrepant or inconclusive results
are referred to the National Reference Laboratory for Toxo-
plasmosis (NRLT) at the Institute for Medical Research in
Belgrade. We present an NRLT-based study of prenatal and/
or early postnatal diagnosis of CT in offspring of women
suspected of toxoplasmosis in pregnancy and of mothers who
have not been tested until after childbirth, using a standardized
approach (reflected in a complex algorithm).
METHODS
Patients
A total of 96 women were enrolled in this prospective
study between September 1, 2008 and August 31, 2014, of
which 80 were tested during pregnancy and 16 after childbirth.
Inclusion criteria for serological testing of pregnant
women included sonographically suspected or documented
fetal malformations and/or suspected toxoplasmosis in preg-
nancy based on serological screening in routine laboratories.
Women first tested after childbirth were included based on
clinical manifestations suggestive of congenital infection in
their neonates.
Among the 80 women tested in pregnancy, prenatal diag-
nosis of CT was conducted in 65 fetuses from 63 pregnancies (2
twin pregnancies). Of these, postpartal follow-up was continued
in 23 neonates.
Postnatal diagnosis of CT was conducted in a total of 55
neonates. These included those 16 with clinical manifes-
tations at birth, born to mothers who have not been tested
during pregnancy, and 39 neonates born to mothers examined
during pregnancy. Of the latter, 23 had been subjected to
prenatal diagnosis, while the mothers of 16 were only
tested serologically.
Biological samples for prenatal diagnosis included amnio-
tic fluid (AF) in 60 and fetal blood (FB) in 5 cases, and for
postnatal diagnosis neonatal blood (NB) samples in all 55 neo-
nates.
The study was approved by the Institute for Medical
Research Ethics Committee (EO103/2014).
Laboratory Methods
All biological materials including peripheral blood, AF,
and FB samples were first centrifuged (2200 rpm for 15 min-
utes), and the supernatant was used for serology while the pellet
(cell material) was used for molecular and biological analysis.
Serological screening of the women was performed on a
VIDAS analyzer, using TXG-VIDAS (<4 IU/mL considered
negative; 4–8 IU/mL borderline and 8 IU/mL positive) and
TXM-VIDAS (results expressed as indices:<0.55 negative,
0.55–0.65 borderline, and 0.65 positive) (bioMérieux, Marcy
l’Etoile, France) assays for specific IgG and IgM detection,
while specific IgG avidity was determined by TXGA-VIDAS
assay (results expressed as indices:<0.200 low, 0.200–0.300
borderline, and 0.300 high avidity) (bioMérieux).
Serology in FB and NB samples included in-house high
sensitivity direct agglutination assay (HSDA)22 for specific IgG
(results expressed as titers; titer 1:40 considered positive), the
antigen for which was kindly provided by Isabelle Villena,
Reims, France, and the immunosorbent agglutination assay
(ISAgA) (bioMérieux) for specific IgM and IgA (results
expressed as indices on a scale from 0 to 12; results 3
considered to be indicative of CT).
Furthermore, neonatal and maternal serological profiles
were compared using the T. gondii Western blot (WB) IgG/IgM
test (LD-Bio Diagnostics, Lyon, France). According to the
manufacturer’s instructions, any well-defined band of a mol-
ecular weight<120 kDa present in the neonate but absent from
the mother’s serum indicates anti-T. gondii antibody neosynth-
esis by the neonate.
All commercial tests were performed according to the
respective manufacturers’ recommendations.
Molecular methods included DNA extraction using 200 mL
of sample by QIAmp DNA mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions, and quantitative
detection of the T. gondii 529 bp repetitive element (AF146527
gene) by real-time PCR (qPCR), using the protocol we
described elsewhere.23
Bioassay (BA) of biological samples in an attempt to
isolate the parasite included intraperitoneal inoculation of
500 mL of sample pellet in 2 Swiss-Webster mice followed
by microscopic examination of mice brain homogenates for T.
gondii cysts and murine serology (HSDA) 6 weeks later. The
detailed protocol was described previously.24
Diagnostic Criteria
The diagnosis of maternal infection was based on serology.
The criteria for the interpretation of the serological results
according to which the examined women were classified into
the infection stages (as acute, subacute, or chronic) are pre-
sented in Table 1. To date maternal infection to the gestational
age, these criteria were further refined to take into account the
time elapsed between testing and the presumed time of infection
(Table 2), based on the following: a positive IgM test, while not
necessarily indicating recent infection, warrants further testing
before a final conclusion can be made; the kinetics of IgG
avidity maturation as shown by the study of Fricker-Hidalgo
et al,25 which showed that a VIDAS avidity index remains under
0.100 during the first 2 to 3 months, and an index of 0.600 is
reached after 9 to 15 months.
The diagnosis of CT relied on direct diagnosis, that is
isolation of the parasite or detection of its DNA, while serolo-
gical findings generally served to complement the diagnosis.
TABLE 1. Serological Criteria for the Determination of the
Toxoplasma gondii Infection Stage in Acquired Toxoplasmosis
Diagnostic Criteria
IgG IgG Avidity IgM
Toxoplasma gondii
Infection Stage
Neg / Neg Seronegative
Pos Low Pos Acute
Pos Border/high Pos Subacute
Pos Low Neg Subacute
Pos Border/high Border Subacute
Pos High Neg Chronic
Border¼ borderline, IgG avidity¼TXGA-VIDAS result for specific
IgG avidity, IgG¼TXG-VIDAS result for specific IgG, IgM¼TXM-
VIDAS result for specific IgM, Neg¼ negative, Pos¼ positive.
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Figure 1 presents the algorithm used for the diagnosis of
CT in the NRLT.
Statistical Analysis
Comparison of the methods used for the diagnosis of CT
was performed using 2 by 2 contingency tables. Standard
parameters of agreement including sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) were determined. Results were statistically
analyzed using the SPSS software, version 11.5 (SPSS
Inc, Chicago, IL). The level of statistical significance was
5% (P<0.05).
TABLE 2. Criteria for the Timing of Toxoplasma gondii Infection Versus Conception in Pregnant Women and After Childbirth
T. gondii Infection Dating Criteria
First Tested IgM IgG Avidity Infection Stage Time of Infection Versus Conception
1st trimester Neg High Chronic >2 m before conception
Pos/border High/border Subacute Periconceptual cannot be excluded
Pos Low (0.100–0.200) Acute Periconceptual
Pos Low (<0.100) Acute 1st trimester
2nd trimester Neg High Chronic >2 m before conception
Pos/border High Subacute Periconceptual cannot be excluded
Pos Border Subacute Periconceptual
Pos Low (0.100–0.200) Acute 1st trimester
Pos Low (<0.100) Acute 2nd trimester
3rd trimester Neg High Chronic >2 m before conception
Pos/border High Subacute Periconceptual
Border Border Subacute 1st trimester
Pos Border Subacute 2nd trimester
Pos Low (0.100–0.200) Acute 2nd trimester
Pos Low (<0.100) Acute 3rd trimester
After delivery Neg High (>0.600) Chronic >2 m before conception; considered of no risk in pregnancy
Neg High (0.300–0.500) Chronic >6 m before delivery but periconceptual cannot be excluded
Border High/border Subacute 1st trimester
Pos High/border Subacute 2nd trimester
Pos Low Acute 3rd trimester
Border¼ borderline, m¼months, Neg¼ negative, Pos¼ positive.
FIGURE 1. Algorithm for the diagnosis of congenital toxoplasmosis. AF¼ amniotic fluid; BA¼bioassay; CT¼congenital toxoplasmosis;
FB¼ fetal blood; HSDA¼high sensitivity direct agglutination assay; IgM-ISAgA¼ ISAgA test for detection of specific IgM, IgA-ISA-
gA¼ ISAgA test for detection of specific IgA, NB¼neonatal blood; qPCR¼quantitative PCR; WB¼Western blot.
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RESULTS
Of the 80 women tested during pregnancy, 22.5% were
examined during the first, 61.3% during the second, and 16.2%
during the third trimester. Only 7 (8.8%) reported lymphadeno-
pathy. Of the 16 women tested because of symptomatic off-
spring, none reported clinical manifestations during pregnancy.
All women were tested serologically for T. gondii-specific IgM
and IgG antibodies as well as for IgG antibody avidity, and the
results interpreted according to the criteria presented in Table 1.
The stage of infection at the time of testing is presented in
Figure 2, and of the time of infection in relation to conception
for infected women in Figure 3. Of all the examined seropo-
sitive women (n¼ 90), infection during pregnancy could not be
ruled out in 93.3%, of which the majority (69%) was dated to the
periconceptual period.
All pregnant women diagnosed with acute or subacute
toxoplasmosis were immediately started on spiramycin treat-
ment. In case of confirmed fetal infection, treatment was
switched to pyrimethamine-sulphadiazine and folinic acid until
delivery, and continued during the entire first year of life of
the neonate.
Prenatal Diagnosis of CT
Of the 80 women tested during pregnancy, 4 were shown to
be noninfected and 3 to be infected long before conception;
these 7 were obviously cases of erroneous diagnosis in a
primary level laboratory. Out of the 73 women with proven
or suspected infection in pregnancy, 63 (86.3%) opted for
prenatal diagnosis of fetal infection.
Direct Diagnosis
Of the 65 prenatal samples, qPCR was performed in 54
(83.1%), of which T. gondii DNA was detected in 11 (20.4%).
Bioassay was performed in 62 (95.4%), and viable parasites
were isolated in 10 (16.1%). CT was diagnosed by qPCR alone
in 7 (41.2%), by both qPCR and BA in 4 (23.5%), and by BA
alone in 6 (35.3%, but in 4 of these qPCR was not performed),
indicating a total of 17 (26%) fetal infections detected by direct
methods. Complete findings in these 17 infected fetuses are
presented in Table 3, with reference to estimated time of
maternal infection versus conception. As presented, CT was
an outcome of infection dated to the periconceptual period in 14
of 17 (82.4%) and to the second trimester in 3 of 17
(17.6%) cases.
Indirect Diagnosis
Specific IgM antibodies (index 3) were detected in 4
(6.1%) prenatal samples (3 AF and 1 FB sample), of which CT
was confirmed in 2 (50%) (Table 3, cases 9, 10). Specific IgA
antibodies were detected in 9 of 15 (60%) samples (8 AF and 1
FB sample), of which CT was proven by direct methods in 5 of 9
(55.6%) (Table 3, cases 5, 7, 8, 9, 14).
Early Postnatal Diagnosis and/or Follow-Up
Postnatal diagnosis of CT was performed in 55 neonates, of
whom 32 (58.2%) were not examined previously. The other 23
(41.8%) were already examined prenatally, when 8 were diag-
nosed with CT.
Direct Diagnosis
Molecular diagnosis of CT was conducted in 41 (74.5%)
neonates, and parasitic DNA was detected in 6 (14.6%). In 1 of
these, the postnatal qPCR result only confirmed the prenatally
established diagnosis (Table 3, case 10), but in the other 5, it
determined the diagnosis of CT (Table 4). The results of
postnatal diagnosis in infected neonates, along with the symp-
tomatology, and results of maternal infection dating are pre-
sented in Table 4.
Of the 41 neonates tested by PCR, 34 mothers had been
examined during pregnancy and prenatal diagnosis of CT had
been performed in 20 (58.8%). Importantly, no PCR result
obtained postnatally reversed any of the negative results of
prenatal molecular diagnosis. In contrast, in 4 cases (Table 3,
cases 13, 14, 15, 17), postnatal PCR was negative despite being
positive prenatally. As 9 of 34 women tested during pregnancy
did not undergo amniocentesis (upon gynecologist’ advice or
personal decision), qPCR was not performed until birth, when it
detected 3 infected infants (Table 4, cases 6–8). Furthermore,
detection of T. gondii DNA in NB was the earliest method of
direct diagnosis for 13 of 16 (81.2%) neonates born to mothers
first tested for toxoplasmosis after delivery, and identified
another 2 infected children (2/13; 15.4%) (Table 4, cases 2
and 4).
Bioassay was performed in 20 (36.4%) neonates. Viable
parasites were isolated in 7 (35%), including 5 (71.4%) neonates
born to mothers examined during pregnancy and 2 (28.6%)
neonates born to mothers tested after childbirth. In 3 of the 4
infected neonates of mothers tested during pregnancy (Table 3,
cases 11, 13, 17), the bioassay result supported the prenatally
FIGURE 2. Stage of Toxoplasma gondii infection in the examined

















FIGURE 3. Dating of Toxoplasma gondii infection versus con-
ception in seropositive women (n¼90).
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established diagnosis, but in 2 (Table 4, cases 6, 7) it was of
diagnostic value (alongside qPCR).
Indirect Diagnosis
Specific IgM antibodies were detected in 7 (12.7%) neo-
nates at birth, but clearance of specific IgM in subsequent
samples in 1 (14.3%) case, along with the negative results of
direct methods, confirmed that the detected antibodies were a
result of contamination during delivery.26 Importantly, all other
6 neonates in which specific IgM antibodies were detected were
CT cases proven by direct methods (Table 3, case 13 and
Table 4, cases 1–5).
Interestingly, in another 2 neonates specific IgM appeared
months after birth, during the fifth (poor compliance with
therapy, diagnosis established at birth) and fifteenth month
of life (serological rebound upon completion of year-long
treatment, CT diagnosed prenatally) (results not shown),
respectively.
TABLE 3. Prenatal Diagnosis of Congenital Toxoplasmosis, With Postnatal Follow-Up and Estimated Time of Maternal Infection
Prenatal Diagnosis Postnatal Diagnosis
Molecular Conventional Molecular Conventional
Case No. qPCR (Ct)
T. gondii




per mL BA WB IgM IgA
Estimated time of
maternal infection
1 ND NA Pos 0 ND / / / / / / Possible periconceptual
2 Pos (35.39) 31 Neg 0 ND / / / / / / Possible periconceptual
3 ND NA Pos 0 ND / / / / / / Possible periconceptual
4 ND NA Pos 0 ND / / / / / / Possible periconceptual
5 Pos (34.30) 74 Neg 0 8 / / / / / / 2nd trimester
6 Pos (35.30) 34 Pos 0 ND / / / / / / Periconceptual
7 Neg NA Pos 0 11 / / / / / / Periconceptual
8 Pos (31.67) 588 Pos 0 4 / / / / / / Possible periconceptual
9

Neg NA Pos 11 12 / / / / / / 2nd trimester
10 Pos (36.96) 9 Neg 3 ND Pos (38.9) <1 ND ND ND ND Periconceptual
11 ND NA Pos 0 ND ND NA Pos ND 0 0 Possible periconceptual
12 Pos (36.72) 11 Pos 0 ND ND NA ND Neg 0 4 Periconceptual
13 Pos (34.60) 58 Neg 0 ND Neg NA Pos Pos 5 4 Periconceptual
14 Pos (35.76) 23 Neg 0 12 Neg NA Neg Neg 0 12 Periconceptual
15 Pos (37.01) 13 Neg 0 0 Neg NA Neg Neg 0 0 Possible periconceptual
16 Pos (36.48) 8 Neg 0 ND ND NA ND Neg 0 0 Possible periconceptual
17 Pos (29.96) 844 Pos 0 0 Neg NA Pos Pos 0 5 2nd trimester
BA¼ bioassay, Ct¼ cycle threshold, IgA¼ ISAgA result for specific IgA, IgM¼ ISAgA result for specific IgM, NA¼ not applicable, ND¼ not
done, /¼ not followed-up postnatally, Neg¼ negative, Pos¼ positive, qPCR¼ quantitative PCR, WB¼Western blot.
FB sample.
TABLE 4. Postnatal Diagnosis of Congenital Toxoplasmosis With Clinical Symptomatology and Estimated Time of Maternal
Infection
Direct Diagnosis Indirect Diagnosis
Case No qPCR (Ct)
T. gondii
per mL BA WB IgM IgA Clinical Symptoms
Estimated time of
maternal infection
1 Neg NA Pos Pos 4 0 NIS, IUGR 3rd trimester
2 Pos (34.70) 20 Neg Pos 12 12 NIS, IUGR 3rd trimester
3 ND NA ND Pos 12 12 Hydrocephalus > 6 months before delivery
(Possible periconceptual)
4 Pos (37.26) 3 Pos Pos 12 11 IUGR 3rd trimester
5 Neg NA ND Pos 3 4 CNS abnormalities > 6 months before delivery
(Possible periconceptual)
6 Pos (34.45) 24 Pos Pos 0 0 Asymptomatic Periconceptual
7 Pos (36.86) 4 Pos Pos 0 5 Asymptomatic 3rd trimester
8 Pos (36.63) 4 Neg Neg 0 0 Asymptomatic Periconceptual
BA¼ bioassay, Ct¼ cycle threshold, IgA¼ ISAgA result for specific IgA, IgM¼ ISAgA result for specific IgM, IUGR¼ intrauterine growth
restriction, NA¼ not applicable, ND¼ not done, Neg¼ negative, NIS¼ nonspecific infectious symptomatology, Pos¼ positive, qPCR¼ quantitative
PCR, WB¼Western blot.
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Specific IgA antibodies, examined in 36 (65.5%), were
detected in 13 (36.1%) neonates, of which CT was proven in 9
(69.2%) (Tables 3 and 4).
WB test was performed in 41 (74.5%) neonates. Among
the 16 neonates diagnosed with CT that were available for
postnatal diagnosis, WB was performed in 14, and neosynthesis
of anti-T. gondii antibody was demonstrated in 9 (64.3%)
(Tables 3 and 4). Of these, 7 were cases of CT diagnosed by
direct methods, whereas in 2 cases of clinical infection a
positive WB was the main diagnostic marker (Table 4, cases
3 and 5). An illustrative example of a positive WB is presented
in Figure 4.
In total, CT was postnatally diagnosed in 8 neonates
(Table 4). In addition, CT was postnatally confirmed in 6 of
the prenatally diagnosed cases, of which in 4 by direct methods
and in 2 only serologically (Table 3, cases 10–14, 17).
Test Comparison
Sensitivity, specificity, PPV, and NPV for each of the
methods used for the diagnosis of CT are presented in Table 5.
The sensitivity and NPV of PCR (80% and 91%, respectively)
exceeded that of bioassay (41.7% and 51.6%, respectively), but
were closely followed by WB (64.3% and 83.9%). Of all the
indirect methods used for the diagnosis of CT, the specificity of
WB was the highest and indeed equal to that of qPCR and BA
(100%).
DISCUSSION
The main prerequisite for evaluating the risk of fetal T.
gondii infection is precise timing of maternal infection versus
conception, which is hampered by the lack of systematic
screening. In this series, we tested women in various stages
of pregnancy and/or after childbirth. The majority of pregnant
women were tested in the second trimester (61.3%), and the
infection was staged as subacute in 58.8%. This is not surprising
given that only few (8.8%) reported lymphadenopathy in the
preceding weeks or months.
Application of a set of criteria based on the kinetics of
specific IgM and maturation of IgG avidity could not rule out
periconceptual infection in even 69% women. Periconceptual
infection is hypothesized to result from delayed parasite
migration from the placenta to the fetus,8,13 weeks and even
months postinfection in the mother, a phenomenon recognized
decades ago as ‘‘prenatal incubation period.’’27 Long con-
sidered to be of low risk for transplacental transmission of
the parasite, resulting in CT in under 2% of the cases,28 recent
studies reported transmission rates after periconceptual infec-
tion of up to 3.3% and 3.8%.29,21 However, the 29% cases of CT
resulting from periconceptual infection is striking. This result
may be attributed to the study sample that, on the one hand,
included a relatively high proportion (25%) of women included
because of fetal/neonatal symptomatology, and on the other, a
relatively high proportion of women (30%) tested late (in the
3rd trimester of pregnancy) or after childbirth, when the dating
of maternal infection could not be more precise and may have
resulted in an overestimation of infection dated to the
periconceptual period.
Overall, using a complex algorithm for the diagnosis of CT
which included molecular, biological, and serological methods,
25 cases of CT were diagnosed in this series. Of these, 17 were
diagnosed prenatally, in cases of proven or suspected infection
during pregnancy or the periconceptual period, while 8 were
diagnosed after birth.
Analysis of the relative contribution of the direct diag-
nostic methods showed that fetal infection was diagnosed by an
optimized qPCR protocol in 85% of the cases where performed
(11/13), of which it was further supported in 4 (of the 11 PCR-
positive cases, 36%) by isolation of viable parasites. On the
other hand, in addition to these 4, bioassay was positive in
another 2 cases in which PCR was negative (of 13, 15%;
Table 3, cases 7 and 9) and in another 4 (where it was the
only direct test performed; Table 3, cases 1, 3, 4, and 11). Thus,
molecular diagnosis was essential in 7 (54%) fetuses in which T.
gondii was not isolated by bioassay. However, failure to detect
T. gondii DNA in 2 cases of parasite isolation may be explained
by a 5-fold higher sample volume inoculated into mice than
used for DNA extraction. In 1 of these cases, the material for
molecular diagnosis was FB, known for high concentrations of
PCR inhibitors which may result in false-negative qPCR. In the
context of these real-life situations, although time-consuming
(5–6 weeks needed for the result), bioassay remains indispen-
sable in prenatal diagnosis of CT.30
Possible reasons for false-negative prenatal diagnosis
include an inadequate time distance between maternal infection
and amniocentesis. AF is generally sampled from the 16th
gestational weeks onward and at least 4 weeks after detectable
maternal seroconversion. However, this is challenging in the
absence of systematic screening and amniocentesis may be
performed too early or too late after maternal infection.
False-negative results are quite common in early pregnancy
seroconverters, due to very few cells and miniscule number of
parasites in AF.31,32 The number of parasites in AF samples
detected by PCR in our study was rather small, below 100/mL in
9 of 11 positive samples, and 88.9% (8/9) of those samples
originated from periconceptually infected women. Maternal
treatment and/or delayed transplacental transmission could
cause the parasites, if at all detectable in AF of periconceptually
infected women, to be present in a small number.8,10,33
As for fetal serology, specific IgM were detected in 11.7%
(2/17), while specific IgA were detected in 29.4% (5/17) of the
infected fetuses, where they obviously reflected the fetal
immune response to T. gondii infection. On the other hand,
specific IgM were detected in 2 and specific IgA antibodies in
FIGURE 4. Representative example of Western blot test showing
fetal neosynthesis of Toxoplasma gondii-specific antibodies at
birth (arrows pointing out to the ‘‘new’’ bands). Left IgG/IgM
strip: maternal serum; right IgG/IgM strip: neonatal serum.
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10 fetuses in which the diagnosis of CT was ultimately
excluded. It has been suggested that specific IgA antibodies
in the AF may be of maternal origin, as a consequence of
passage due to increased placental permeability.34
Among the 55 studied neonates, CT was diagnosed pre-
natally in 8, while in another 8, CT was first diagnosed after
birth. Of the latter, the diagnosis was based on PCR in 5 (of the 7
in which it was performed, 71.4%) and on bioassay in 1 (of 8,
12.5%). In 2 neonates (25%), however, it was based on the
results of indirect methods (WB, ISAgA) only (Table 4, cases 3
and 5); notably, both had severe CNS abnormalities.
NB is not considered an ideal material for molecular
diagnosis of CT because, if the infection was transmitted long
before delivery, parasitemia is rarely detectable in the neonate,
especially if the mother was treated during pregnancy.35 How-
ever, it allowed us to diagnose CT in 2 neonates with very low
parasitemia and negative bioassay (20 and 4 parasites/mL,
respectively). Generally, the parasitic load determined by qPCR
was remarkably low, ranging from 3 to 24 parasites/mL. Bear-
ing in mind that the sensitivity of bioassay is 10 cysts/mL, the
low number of parasites in the above cases may have easily
remained undetected by conventional methods of parasite iso-
lation. Overall, the qPCR protocol applied in this study had a
91% NPV and 80% sensitivity, nearly twice as high as the
sensitivity of bioassay (41.7%).
Specific IgM and IgA antibodies were detected in 37.5%
(6/16) and 56% (9/16) of infected neonates, respectively.
Previous studies have shown that specific IgM and IgA are
usually detected in neonates after third trimester infections,36
which accounted for only 7.8% of the postnatal diagnoses in our
series (Figure 3). More frequent detection of specific IgA than
specific IgM antibodies in infected neonates born to women
infected in early pregnancy has been reported.37
WB is the most reliable serological marker of CT.18,38,39
Of the neonates with positive WB in our series, specific IgM and
specific IgA antibodies were both undetectable in 11.1% (1/9),
and alone in another 22.2% (2/9) and 11.1% (1/9), respectively.
The WB result supported the diagnosis of CT in 7 of 8 (87.5%)
postnatally diagnosed neonates. The specificity of WB paral-
leled that of the direct methods (100%); furthermore, it was the
crucial diagnostic marker in 2 neonates, in 1 of which PCR was
negative while direct diagnostic methods were not performed in
the other. However, WB was negative in 5 infected neonates, all
born to periconceptually infected mothers (Table 3, cases 12,
14–16; Table 4, case 8). In these neonates, the diagnosis was
based on positive qPCR, lending further support to the super-
iority of molecular over serological diagnosis in early preg-
nancy or periconceptual infection.
Although this study did not aim to analyze treatment
effects, it should be noted that no (additional) clinical
manifestations were observed at birth in any of the diagnosed
and treated CT cases, as opposed to clinical CT in unrecog-
nized cases of maternal infection during pregnancy (Table 4,
cases 1–5). This further emphasizes the significance of
early diagnosis.
In conclusion, early diagnosis of maternal and subsequent
fetal T. gondii infection is a prerequisite for early treatment.
This is best achieved by systematic screening in pregnancy, a
practice unfortunately limited to very few countries. In the
rather universal situation of a no screening in pregnancy policy,
the results of this study show that the use of a combination of
serological, biological, and molecular methods to date
maternal infection and diagnose CT may help equalize the
opportunities for a T. gondii-free life to offspring regardless of
the national health policy. This approach, however, still lacks
the preventive capacity provided by early maternal treatment
and is associated with increased costs and unnecessary anxiety
in a number of pregnant women while awaiting the results
and outcome.
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